

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3415762

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
TES PHARMA S.R.L.	01/25/2015
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	INTERCEPT PHARMACEUTICALS, INC.
<b>Street Address:</b>	450 W. 15TH STREET
<b>Internal Address:</b>	SUITE 505
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10011
<b>PROPERTY NUMBERS Total: 3</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	14120366
<b>Application Number:</b>	61823169
<b>PCT Number:</b>	EP2014059896
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6467572327
<b>Email:</b>	ip.docketing@interceptpharma.com, angel.matos@interceptpharma.com, michelle.iwamoto-fan@interceptpharma.com
<b>Correspondent Name:</b>	INTERCEPT PHARMACEUTICALS, INC.
<b>Address Line 1:</b>	450 W. 15TH STREET
<b>Address Line 2:</b>	SUITE 505
<b>Address Line 4:</b>	NEW YORK, NEW YORK 10011
<b>ATTORNEY DOCKET NUMBER:</b>	IPHA-020
<b>NAME OF SUBMITTER:</b>	ANGEL L. MATOS
<b>SIGNATURE:</b>	/Angel L. Matos/
<b>DATE SIGNED:</b>	06/26/2015
<b>Total Attachments: 2</b>	

source=Intercept TES- Invention and Patent Assignment (1-25-2015) Fully Executed#page1.tif

source=Intercept TES- Invention and Patent Assignment (1-25-2015) Fully Executed#page2.tif

**ASSIGNMENT OF INVENTION AND PATENTS THEREON**


WHEREAS, TES PHARMA S.R.L., a corporation organized and existing under the laws of Italy and having a registered office at Via Palmiro Togliatti 20, 06073 Corciano (Loc. Taverne), Perugia, Italy ("**TES**"), is the owner of the patent(s) and/or patent application(s) listed in the attached Exhibit; and

WHEREAS, INTERCEPT PHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware and having a registered office at 450 W 15th Street, Suite 505, New York, NY 10011, USA ("**INTERCEPT**"), desires to acquire the entire interest in and to the subject-matter disclosed in these applications and in and to all patents issued or to be issued thereon;

NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN: Be it known that for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, TES does hereby sell, assign, transfer and set over unto INTERCEPT the entire right, title and interest in and to all Letters Patent listed herein, and in and to the subject matter disclosed therein, and any continuations, divisions, renewals, substitutes or reissues thereof, and in and to all Letters Patent Domestic and Foreign issued or to be obtained thereon, including all rights and interests with priority rights under the Paris Convention for the Protection of Industrial Property, the International Patent Cooperative Union, European Patent Convention, Common Market Convention, or any other Convention or Union for each country of said Convention or Union, the same to be held and enjoyed by INTERCEPT to the end of the term or terms for which the Letters Patents are or may be granted or reissued as fully and entirely as the same would have been held by INTERCEPT had said sale, transfer and assignment not been made; together with all claims for damages by reason of past infringement of the Letters Patents, with a right to sue for, and collect same for its own use, and for the use of its successors, assigns or other legal representatives; and TES hereby ratifies and confirms in all respects the aforesaid sale, transfer and assignment of the inventions, applications for Letters Patents, and Letters Patents to INTERCEPT.

Witness my hand this \_\_\_\_\_ day of \_\_\_\_\_, 2015.

TES PHARMA S.R.L.

By:   
Name: Roberto Pellicciari  
Title: \_\_\_\_\_

**EXHIBIT A**

Country	Application No.	Appl. Date	Status	Pub. No.	Pub. Date
US	14/120,366	5/14/2014	Published	US-2014-0371190-A1	12/18/2014
PCT	PCT/EP2014/059896	5/14/2014	Published	WO 2014/184271	11/20/2014
US	61/823,169	5/14/2013	Expired		